Clinical Trial Update: Omalizumab to Accelerate a Symptom-driven Multi-food OIT [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial evaluating omalizumab to accelerate symptom-driven multi-food oral immunotherapy in individuals with food allergy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Philippe Bégin | Conditions: Food IgE-mediated Allergy, Immunotherapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING